A new analysis from the CANTOS trial shows that individuals who initially respond to canakinumab benefit the most from this new drug as regards cardiovascular events. This sub-analysis presented at the American Heart Association 2017 Scientific Sessions and simultaneously published in the Lancet showed that the magnitude of the reduction in C-reactive protein following a…